Claritev (CTEV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Annual Meeting scheduled for April 29, 2026, to be held virtually, with record date March 6, 2026.
2025 marked a return to positive revenue growth, improved Adjusted EBITDA, and strong free cash flow.
Strategic focus on Vision 2030, digital transformation, and disciplined growth through technology and AI.
Expanded into new vertical markets and secured over $67 million in new Annual Contract Value.
Voting matters and shareholder proposals
Four proposals: (1) Election of four Class III directors, (2) Ratification of PwC as auditor, (3) Advisory say-on-pay vote, (4) Approval of amendment to 2020 Omnibus Incentive Plan.
Board recommends voting FOR all proposals.
Shareholders can vote by internet, phone, or mail; virtual attendance allows for proxy revocation and live voting.
Board of directors and corporate governance
Board consists of ten members with one vacancy; 80% are independent.
Board divided into three staggered classes; Lead Independent Director role in place.
Committees: Audit, Compensation, Nominating & Corporate Governance, and Risk—all fully independent.
Board diversity in experience, background, gender, age, and race.
Annual board and committee self-evaluations and director education programs.
Latest events from Claritev
- Definitive additional proxy materials outline voting procedures for the upcoming meeting.CTEV
Proxy filing20 Mar 2026 - 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and tech-driven growth.CTEV
Investor Day 202620 Mar 2026 - Record bookings, robust AI-driven growth, and disciplined investment fuel expansion.CTEV
Status update6 Mar 2026 - Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEV
Q4 202523 Feb 2026 - Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEV
Q2 20242 Feb 2026 - Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEV
Q3 202416 Jan 2026 - Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - 2024 revenue declined 3.2% and net loss spiked on impairment as transformation accelerates.CTEV
Q4 202423 Dec 2025 - Healthcare cost management firm files to offer up to $400M in securities for growth and operations.CTEV
Registration Filing16 Dec 2025